| | |
| Clinical data | |
|---|---|
| Other names | AZD9833 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H28F4N6 |
| Molar mass | 476.524 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Camizestrant is an investigational new drug that is being evaluated to treat breast cancer. [1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD). [2]